1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may link to a different grant program than the one shown here.
We recommend visiting the funder’s website directly to confirm this opportunity is available.
Search verified grants from The High Q Foundation Inc. →This listing may be outdated. Verify details at the official source before applying.
Find similar grantsRolling submissions; CHDI reviews initial summaries and invites full proposals on a case-by-case basis with ~4 weeks initial review plus 3-6 months for agreement execution.
Academic Research Proposals is sponsored by The High Q Foundation Inc.. CHDI Foundation (formerly The High Q Foundation Inc.) funds and collaborates with academic researchers worldwide to develop therapeutics for Huntington's disease.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Academic Proposals | CHDI Foundation CHDI Foundation is exclusively dedicated to collaboratively developing therapeutics that will substantially improve the lives of individuals with HD.
To prioritize where our resources will be most effective in HD therapeutic development, we have organized our preclinical research programs into four interconnected Thematic Areas that focus on what we consider the most promising therapeutic areas and the means to pharmacologically interrogate them; namely 1) targeting mutant huntingtin DNA, RNA, and protein, 2) targeting somatic instability and mismatch handling and repair mechanisms related to modifier genes, 3) targeting the non-mismatch repair genetic modifiers, and 4) targeting gene editing of the causative triplet repeat mutation in the huntingtin gene.
To implement our diverse research portfolio, we fund and work with academic researcher colleagues around the world. CHDI is not a general research funding body that issues financial grants, nor do we have a research proposal submission cycle.
However, we are receptive to novel ideas and will explore new areas of biology that have relevance to HD, particularly when there is either robust human data evidence or the therapeutic approach has disease-modifying potential. Initial proposals are reviewed on a rolling basis by team members.
If we are interested in your proposal, then a science director will invite you to submit a full proposal and budget for further review and consideration – see the schematic below. If we are interested in funding your research proposal then typically CHDI and your research institution will enter into a research agreement that defines a detailed project description, milestones with deliverables, and a specific budget.
CHDI scientists will be involved in the design and oversight of the project and will work with you to develop a mutually agreeable research plan. The investigator must conduct the research as specified in the contract and deliver progress reports to receive continued support.
Under our standard research agreement, the research institution owns the data and intellectual property generated during the project and has the sole and exclusive right to publish. If you would like to apply for research funding from CHDI then please submit a short summary of your proposal to . Typical timeline for proposal consideration : Frequently Asked Questions How long does it take to process an academic research proposal?
Proposals will be assigned to the most relevant Thematic Area and reviewed extensively by our science directors. Initial review usually takes about 4 weeks. If there is mutual interest to enter into a research agreement, a work plan and budget will be drafted by the principal investigator and CHDI science director; agreement execution may take an additional 3-6 months.
Does CHDI give access to materials, reagents, animals, or specialized services? Dependent upon project specifics, CHDI can make certain materials, such as reagents, antibodies, cell lines, animal models, and human biosamples, available to the collaborating academic laboratory, as well as specialized third-party services (e.g., HTT assays, sequencing, etc.). What kind of costs are included in CHDI funding?
CHDI has a detailed budget policy . We support standardized full-time employee costs for postdocs and experienced research personnel, consumables, animals, and various other costs, including limited travel, publication, and overhead. CHDI does not normally support graduate students, training, administrative staff, equipment costs, or office supplies.
function show_popup_email() document. getElementById('popup_email'). style.
display="block"; function hide_popup_email() document. getElementById('popup_email'). style.
display="none"; function show_popup_terms() document. getElementById('terms'). style.
display="block"; function hide_popup_terms() document. getElementById('terms'). style.
display="none"; function show_popup_policy() document. getElementById('policy'). style.
display="block"; function hide_popup_policy() document. getElementById('policy'). style.
display="none"; Click to read a letter from Robert Pacifici, CHDI CSO, regarding COVID-19
According to the current listing, eligibility includes: Academic faculty, post-doctoral fellows, and technical staff at research institutions globally. Confirm the full requirements in the official notice before applying.
Academic Research Proposals is funded by The High Q Foundation Inc.. Verify program details on the funder's official page before applying.
This listing is flagged as international in scope. Check the official notice for country-specific restrictions before applying.
On September 3, 2026 — six days before the FY2027 Pioneer deadline — NIH posted forecast records for the entire FY2028 High-Risk, High-Reward program. The slate is nearly flat against FY2027, Transformative loses a slot, and the dollar figures quietly assume full negotiated indirect rates.
Read articleThe U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read articleThe FY2027 Common Fund slate is roughly $44 million across about 54 awards — Pioneer at $8M for 7, Transformative at $8M for 7, Early Independence at $5.7M for 10, and New Innovator's 30 already closed on August 17. Early Independence skipped FY2026 entirely, and its degree-eligibility window now spans 29 months to absorb the gap.
Read article